Literature DB >> 10691218

Pharmacokinetics of dopamine in healthy male subjects.

D A MacGregor1, T E Smith, R C Prielipp, J F Butterworth, R L James, P E Scuderi.   

Abstract

BACKGROUND: Dopamine is an agonist of alpha, beta, and dopaminergic receptors with varying hemodynamic effects depending on the dose of drug being administered. The purpose of this study was to measure plasma concentrations of dopamine in a homogeneous group of healthy male subjects to develop a pharmacokinetic model for the drug. Our hypothesis was that dopamine concentrations can be predicted from the infusion dose using a population-based pharmacokinetic model.
METHODS: Nine healthy male volunteers aged 23 to 45 yr were studied in a clinical research facility within our academic medical center. After placement of venous and arterial catheters, dopamine was infused at 10 microg x kg(-1) x min(-1) for 10 min, followed by a 30-min washout period. Subsequently, dopamine was infused at 3 microg x kg(-1) x min(-1) for 90 min, followed by another 30-min washout period. Timed arterial blood samples were centrifuged, and the plasma was analyzed by high-performance liquid chromatography. Mixed-effects pharmacokinetic models using NONMEM software (NONMEM Project Group, University of California, San Francisco, CA) were used to determine the optimal compartmental pharmacokinetic model for dopamine.
RESULTS: Plasma concentrations of dopamine varied from 12,300 to 201,500 ng/l after 10 min of dopamine infusion at 10 microg x kg(-1) x min(-1). Similarly, steady-state dopamine concentrations varied from 1,880 to 18,300 ng/l in these same subjects receiving 3-microg x kg(-1) x min(-1) infusions for 90 min. A two-compartment model adjusted for body weight was the best model based on the Schwartz-Bayesian criterion.
CONCLUSIONS: Despite a homogeneous population of healthy male subjects and weight-based dosing, there was 10- to 75-fold intersubject variability in plasma dopamine concentrations, making standard pharmacokinetic modeling of less utility than for other drugs. The data suggest marked intraindividual and interindividual variability in dopamine distribution and/or metabolism. Thus, plasma dopamine concentrations in patients receiving dopamine infusion at identical rates may vary profoundly. Our data suggest that dosing dopamine based on body weight does not yield predictable blood concentrations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10691218     DOI: 10.1097/00000542-200002000-00013

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  8 in total

1.  Cardiac platypnea-orthodeoxia syndrome in a 73-year-old woman.

Authors:  Khai-Jing Ng; Yi-Da Li
Journal:  CMAJ       Date:  2015-07-20       Impact factor: 8.262

2.  Positive inotropes in heart failure: a review article.

Authors:  Ahmad Amin; Majid Maleki
Journal:  Heart Asia       Date:  2012-01-01

3.  Dopamine is a safe antiangiogenic drug which can also prevent 5-fluorouracil induced neutropenia.

Authors:  Chandrani Sarkar; Debanjan Chakroborty; Partha Sarathi Dasgupta; Sujit Basu
Journal:  Int J Cancer       Date:  2015-01-07       Impact factor: 7.396

Review 4.  Dosing of medications in morbidly obese patients in the intensive care unit setting.

Authors:  Brian L Erstad
Journal:  Intensive Care Med       Date:  2003-11-19       Impact factor: 17.440

5.  Pharmacokinetics and pharmacodynamics of dopamine and norepinephrine in critically ill head-injured patients.

Authors:  Andrew J Johnston; Luzius A Steiner; Mark O'Connell; Dot A Chatfield; Arun K Gupta; David K Menon
Journal:  Intensive Care Med       Date:  2003-10-29       Impact factor: 17.440

6.  Comparing the Rates of Dopamine Hemodynamic Effect Onset after Infusion through Peripheral Veins in Three Regions.

Authors:  Deokkyu Kim; Ji-Seon Son; Won-Young Choi; Young-Jin Han; Jun-Rae Lee; Hyungsun Lim
Journal:  Korean J Crit Care Med       Date:  2017-01-24

7.  Relationship between Urinary N-Desmethyl-Acetamiprid and Typical Symptoms including Neurological Findings: A Prevalence Case-Control Study.

Authors:  Jemima Tiwaa Marfo; Kazutoshi Fujioka; Yoshinori Ikenaka; Shouta M M Nakayama; Hazuki Mizukawa; Yoshiko Aoyama; Mayumi Ishizuka; Kumiko Taira
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

8.  Dopamine adjusts the circadian gene expression of Per2 and Per3 in human dermal fibroblasts from ADHD patients.

Authors:  Frank Faltraco; Denise Palm; Adriana Uzoni; Lena Borchert; Frederick Simon; Oliver Tucha; Johannes Thome
Journal:  J Neural Transm (Vienna)       Date:  2021-07-18       Impact factor: 3.575

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.